BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension

Status:	Active, not recruiting
Conditions:	High Blood Pressure (Hypertension), High Blood Pressure (Hypertension)
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	18 - 80
Updated:	4/6/2019
Start Date:	July 1, 2009
End Date:	November 29, 2019

Long-term Extension, Multicentre, Multi-international Study to Evaluate the Safety and Tolerability of Oral BAY63-2521 (1mg, 1.5 mg, 2.0 mg, 2.5 mg Tid) in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Patients who have completed the 16 weeks treatment of the CHEST-1 trial (study number 11348)
will be asked to participate in this long term extension study with BAY63-2521. The aim of
the long term study is to collect additional information to evaluate the safety and
tolerability of BAY63-2521. Patients will be treated with open label medication on their
individual optimal dose between 0,5 mg - 2,5 mg tid.

Inclusion Criteria:

- Patients who have completed 16 weeks of treatment in the double blind trial CHEST 1

Exclusion Criteria:

- Patients who have an ongoing serious adverse event from CHEST 1 that is assessed as
related to BAY63-2521 are not allowed to participate in the extension trial.

We found this trial at

sites

Clinical Trial Facility in Cleveland Ohio

Cleveland, Ohio

from

Cleveland, OH